Ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia with 17p deletion (RESONATE-17): a phase 2, open-label, multicentre study by O'Brien, Susan, Prof, Jones, Jeffrey A, MD, Coutre, Steven E, Prof, Mato, Anthony R, MD, Hillmen, Peter, Prof, Tam, Constantine, MD, Österborg, Anders, Prof, Siddiqi, Tanya, MD, Thirman, Michael J, MD, Furman, Richard R, MD, Ilhan, Osman, Prof, Keating, Michael J, Prof, Call, Timothy G, MD, Brown, Jennifer R, MD, Stevens-Brogan, Michelle, MSc, Li, Yunfeng, PhD, Clow, Fong, ScD, James, Danelle F, MD, Chu, Alvina D, MD, Hallek, Michael, Prof, Stilgenbauer, Stephan, Prof

Get full text

Venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia: a phase 1b study by Seymour, John F, Prof, Ma, Shuo, MD, Brander, Danielle M, MD, Choi, Michael Y, MD, Barrientos, Jacqueline, MD, Davids, Matthew S, MD, Anderson, Mary Ann, MBBS, Beaven, Anne W, MD, Rosen, Steven T, Prof, Tam, Constantine S, MD, Prine, Betty, BS, Agarwal, Suresh K, PhD, Munasinghe, Wijith, PhD, Zhu, Ming, PhD, Lash, L Leanne, PhD, Desai, Monali, MD, Cerri, Elisa, MD, Verdugo, Maria, MD, Kim, Su Young, MD, Humerickhouse, Rod A, MD, Gordon, Gary B, MD, Kipps, Thomas J, Prof, Roberts, Andrew W, Prof

Get full text

Ibrutinib Versus Ofatumumab in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): Results From the Randomized Phase III RESONATE™ (PCYC-1112) Tri... by Brown, J. Jennifer R., MD, PhD, Byrd, John C., MD, O’Brien, Susan, MD, Barrientos, Jacqueline C., MD, Kay, Neil E., MD, Reddy, Nishitha M., MBBS, MD, Coutre, Steven, MD, Tam, Constantine S., MBBS, MD, Mulligan, Stephen, MBBS, PhD, FRACP, FRCPA, Jaeger, Ulrich, MD, Devereux, Stephen, PhD, FRCP, FRCPath, Barr, Paul M., MD, Furman, Richard, MD, Kipps, Thomas, MD, PhD, Cymbalista, Florence, MD, PhD, Fardis, Maria, PhD, MBA, McGreivy, Jesse, MD, Clow, Fong, DSc, James, Danelle F., MD, MAS, Hillmen, Peter, MD, PhD, FRCP, FRCPath

Get full text

Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study by Schuster, Stephen J, MD, Tam, Constantine S, MD, Borchmann, Peter, MD, Worel, Nina, MD, McGuirk, Joseph P, DO, Holte, Harald, MD, Waller, Edmund K, MD, Jaglowski, Samantha, MD, Bishop, Michael R, MD, Damon, Lloyd E, MD, Foley, Stephen Ronan, MD, Westin, Jason R, MD, Fleury, Isabelle, MD, Ho, P Joy, MBBS, Mielke, Stephan, MD, Teshima, Takanori, MD, Janakiram, Murali, MD, Hsu, Jing-Mei, MD, Izutsu, Koji, MD, Kersten, Marie José, MD, Ghosh, Monalisa, MD, Wagner-Johnston, Nina, MD, Kato, Koji, MD, Corradini, Paolo, MD, Martinez-Prieto, Marcela, MD, Han, Xia, MS, Tiwari, Ranjan, MSc, Salles, Gilles, MD, Maziarz, Richard T, MD

Get full text

Zanubrutinib versus bendamustine and rituximab in untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (SEQUOIA): a randomised, controlled, phase 3 trial by Tam, Constantine S, Prof, Brown, Jennifer R, Prof, Kahl, Brad S, Prof, Ghia, Paolo, Prof, Giannopoulos, Krzysztof, Prof, Jurczak, Wojciech, Prof, Šimkovič, Martin, MD, Shadman, Mazyar, MD, Österborg, Anders, MD, Laurenti, Luca, Prof, Walker, Patricia, MBBS, Opat, Stephen, Prof, Chan, Henry, MBChB, Ciepluch, Hanna, PhD, Greil, Richard, Prof, Tani, Monica, MD, Trněný, Marek, Prof, Brander, Danielle M, MD, Flinn, Ian W, MD, Grosicki, Sebastian, MD, Verner, Emma, MBBS, Tedeschi, Alessandra, MD, Li, Jianyong, MD, Tian, Tian, PhD, Zhou, Lei, MD, Marimpietri, Carol, RN, Paik, Jason C, MD, Cohen, Aileen, MD, Huang, Jane, MD, Robak, Tadeusz, Prof, Hillmen, Peter, Prof

Get full text

Ibrutinib for patients with rituximab-refractory Waldenström's macroglobulinaemia (iNNOVATE): an open-label substudy of an international, multicentre, phase 3 trial by Dimopoulos, Meletios A, Dr Prof, Trotman, Judith, Prof, Tedeschi, Alessandra, MD, Matous, Jeffrey V, Prof, Macdonald, David, MD, Tam, Constantine, MBBS, Tournilhac, Olivier, Prof, Ma, Shuo, MD, Oriol, Albert, MD, Heffner, Leonard T, MD, Shustik, Chaim, Prof, García-Sanz, Ramón, Prof, Cornell, Robert F, MD, de Larrea, Carlos Fernández, MD, Castillo, Jorge J, MD, Granell, Miquel, MD, Kyrtsonis, Marie-Christine, MD, Leblond, Veronique, Prof, Symeonidis, Argiris, MD, Kastritis, Efstathios, MD, Singh, Priyanka, MS, Li, Jianling, MS, Graef, Thorsten, MD, Bilotti, Elizabeth, MSN, Treon, Steven, MD, Buske, Christian, Prof

Get full text

Ibrutinib plus venetoclax in relapsed or refractory mantle cell lymphoma (SYMPATICO): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study by Wang, Michael, Prof, Jurczak, Wojciech, Prof, Trneny, Marek, Prof, Belada, David, MD, Wrobel, Tomasz, MD, Ghosh, Nilanjan, MD, Keating, Mary-Margaret, MD, van Meerten, Tom, MD, Alvarez, Ruben Fernandez, MD, von Keudell, Gottfried, MD, Thieblemont, Catherine, Prof, Peyrade, Frederic, MD, Andre, Marc, MD, Hoffmann, Marc, MD, Szafer-Glusman, Edith, PhD, Lin, Jennifer, MS, Dean, James P, MD, Neuenburg, Jutta K, MD, Tam, Constantine S, Prof

Get full text

An unappreciated cell survival-independent role for BAFF initiating chronic lymphocytic leukemia by Ullah, Md Ashik, Garcillán, Beatriz, Whitlock, Eden, Figgett, William A, Infantino, Simona, Eslami, Mahya, Yang, SiLing, Rahman, M Arifur, Sheng, Yong H, Weber, Nicholas, Schneider, Pascal, Tam, Constantine S, Mackay, Fabienne

Get full text